The U.S. Food and Drug Administration (FDA) has approved Myqorzo® (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), denoting a major advancement in targeted pharmacologic management of this complex structural heart disease. Obstructive hypertrophic cardiomyopathy is a genetic myocardial disorder characterized by pathologic thickening of the ventricular myocardium, most notably involving…